Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

The company is one of the first in China to focus on innovative antibody drug research and continues to actively innovate. It has a mature platform integrating research, production and marketing, and focuses on new technology research such as monoclonal antibodies, double antibodies, multiple antibodies and multifunctional recombinant proteins. The company has more than 18 years of large-scale antibody industrialization and quality control experience, and has laid out the CDMO business in multiple dimensions to consolidate and enhance its leading position as an innovative therapeutic drug enterprise. Currently, the company has 13 innovative drugs under development at various stages of development. Most of the drugs under development are Class 1 therapeutic biological products, and some of the drugs under development are double reported by China and the US. The company's main business is R&D, production and sales of antibody drugs. The company's main products: Exaipu (recombinant human type II tumor necrosis factor receptor-antibody fusion protein), cyptine (injectable initumab), and Genitumab (recombinant anti-CD25 humanized monoclonal antibody injection). The company has a national engineering research center for antibody drugs, and has received support for major national scientific research projects such as 8 national “major new drug creation” major science and technology projects, 4 national high-tech research and development plans (“863 plans”), 3 national strategic emerging industry development special fund plans, 1 national independent innovation and high-tech industrialization project, 1 national high-tech industry development project plan, and 1 national major scientific and technological achievement transformation project.